-
Cardiac magnetic resonance biomarkers as surrogate endpoints in cardiovascular trials for myocardial diseases Eur. Heart J. (IF 39.3) Pub Date : 2023-09-13 Dominik C Benz, Christoph Gräni, Panagiotis Antiochos, Bobak Heydari, Mark Colin Gissler, Yin Ge, Sarah A M Cuddy, Sharmila Dorbala, Raymond Y Kwong
Cardiac magnetic resonance offers multiple facets in the diagnosis, risk stratification, and management of patients with myocardial diseases. Particularly, its feature to precisely monitor disease activity lends itself to quantify response to novel therapeutics. This review critically appraises the value of cardiac magnetic resonance imaging biomarkers as surrogate endpoints for prospective clinical
-
Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial Eur. Heart J. (IF 39.3) Pub Date : 2023-08-31 Lama Ghazi, Yu Yamamoto, Michael Fuery, Kyle O’Connor, Sounok Sen, Marc Samsky, Ralph J Riello, Ravi Dhar, Joanna Huang, Temitope Olufade, James McDermott, Silvio E Inzucchi, Eric J Velazquez, Francis Perry Wilson, Nihar R Desai, Tariq Ahmad
Background and Aims Patients hospitalized for acute heart failure (AHF) continue to be discharged on an inadequate number of guideline-directed medical therapies (GDMT) despite evidence that inpatient initiation is beneficial. This study aimed to examine whether a tailored electronic health record (EHR) alert increased rates of GDMT prescription at discharge in eligible patients hospitalized for AHF
-
Recommendations for statin management in primary prevention: disparities among international risk scores Eur. Heart J. (IF 39.3) Pub Date : 2023-08-28 G B John Mancini, Arnold Ryomoto, Eunice Yeoh, Liam R Brunham, Robert A Hegele
Background and Aims Statin recommendations in primary prevention depend upon risk algorithms. Moreover, with intermediate risk, risk enhancers and de-enhancers are advocated to aid decisions. The aim of this study was to compare algorithms used in North America and Europe for the identification of patients warranting statin or consideration of risk enhancers and de-enhancers. Methods A simulated population
-
Type A aortic dissection: optimal annual case volume for surgery Eur. Heart J. (IF 39.3) Pub Date : 2023-08-28 Michal J Kawczynski, Sander M J van Kuijk, Jules R Olsthoorn, Jos G Maessen, Suzanne Kats, Elham Bidar, Samuel Heuts
Background and Aims The current study proposes a novel volume–outcome (V–O) meta-analytical approach to determine the optimal annual hospital case volume threshold for cardiovascular interventions in need of centralization. This novel method is applied to surgery for acute type A aortic dissection (ATAAD) as an illustrative example. Methods A systematic search was applied to three electronic databases
-
Prevalence and Incidence of Diastolic Dysfunction in Atrial Fibrillation: Clinical Implications Eur. Heart J. (IF 39.3) Pub Date : 2023-08-28 Jwan A Naser, Eunjung Lee, Christopher G Scott, Austin M Kennedy, Patricia A Pellikka, Grace Lin, Sorin V Pislaru, Barry A Borlaug
Background and Aims Atrial fibrillation (AF) and heart failure with preserved ejection fraction (HFpEF) are intimately associated disorders. HFpEF may be overlooked in AF when symptoms are simply attributed to dysrhythmia, and incident AF may identify patients at risk for developing diastolic dysfunction (DD). This study aimed to investigate the prevalence and incidence of DD in patients with new-onset
-
Critical limb-threatening ischemia and microvascular transformation: clinical implications Eur. Heart J. (IF 39.3) Pub Date : 2023-08-27 Santeri Tarvainen, Galina Wirth, Greta Juusola, Olli Hautero, Kari Kalliokoski, Tanja Sjöros, Veikko Nikulainen, Jouni Taavitsainen, Jarkko Hytönen, Crister Frimodig, Krista Happonen, Tuomas Selander, Tomi Laitinen, Harri H Hakovirta, Juhani Knuuti, Nihay Laham-Karam, Juha Hartikainen, Kimmo Mäkinen, Seppo Ylä-Herttuala, Petra Korpisalo
Background and aims Clinical management of critical limb-threatening ischemia (CLTI) is focused on prevention and treatment of atherosclerotic arterial occlusions. The role of microvascular pathology in disease progression is still largely unspecified and more importantly not utilized for treatment. The aim of this explorative study was to characterize the role of the microvasculature in CLTI pathology
-
New-onset atrial fibrillation in chronic coronary syndrome: the CLARIFY registry Eur. Heart J. (IF 39.3) Pub Date : 2023-08-27 Alexandre Gautier, Fabien Picard, Gregory Ducrocq, Yedid Elbez, Kim M Fox, Roberto Ferrari, Ian Ford, Jean-Claude Tardif, Michal Tendera, Philippe Gabriel Steg
Background and Aims Data on new-onset atrial fibrillation (NOAF) in patients with chronic coronary syndromes (CCS) are scarce. This study aims to describe the incidence, predictors and impact on cardiovascular outcomes of NOAF in CCS patients. Methods Data from the international (45 countries) CLARIFY registry (prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY
-
Coronary Flow Capacity And Survival Prediction After Revascularization: Physiological Basis And Clinical Implications Eur. Heart J. (IF 39.3) Pub Date : 2023-08-27 K Lance Gould, Nils P Johnson, Amanda E Roby, Linh Bui, Danai Kitkungvan, Monica B Patel, Tung Nguyen, Richard Kirkeeide, Mary Haynie, Salman A Arain, Konstantinos Charitakis, Abhijeet Dhoble, Richard Smalling, Angelo Nascimbene, Marwan Jumean, Sachin Kumar, Biswajit Kar, Stefano Sdringola, Anthony Estrera, Igor Gregoricm, Dejian Lai, Ruosha Li, David McPherson, Jagat Narula
Background and Aims Coronary Flow Capacity (CFC) associates with an Observed 10-yearsurvival probability for individual patients before and after actual revascularization for comparison to Virtual hypothetical ideal complete revascularization. Methods Stress myocardial perfusion (mL/min/g) and coronary flow reserve (CFR) per pixel were quantified in 6979 coronary artery disease (CAD) subjects using
-
Five-year major cardiovascular events are increased when coronary revascularization is guided by instantaneous wave-free ratio compared to fractional flow reserve: a pooled analysis of iFR-SWEDEHEART and DEFINE-FLAIR trials Eur. Heart J. (IF 39.3) Pub Date : 2023-08-27 Ashkan Eftekhari, Emil Nielsen Holck, Jelmer Westra, Niels Thue Olsen, Niels Henrik Bruun, Lisette Okkels Jensen, Thomas Engstrøm, Evald Høj Christiansen
Background and Aims Guidelines recommend revascularization of intermediate epicardial artery stenosis to be guided by evidence of ischemia. Fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) are equally recommended. Individual 5-year results of two major randomized trials comparing FFR with iFR-guided revascularization suggested increased all-cause mortality following iFR-guided
-
Dipeptidyl peptidase 3 plasma levels predict cardiogenic shock and mortality in acute coronary syndromes Eur. Heart J. (IF 39.3) Pub Date : 2023-08-26 Florian A Wenzl, Francesco Bruno, Simon Kraler, Roland Klingenberg, Alexander Akhmedov, Stefano Ministrini, Karine Santos, Konstantin Godly, Julia Godly, David Niederseer, Robert Manka, Andreas Bergmann, Giovanni G Camici, Arnold von Eckardstein, Barbara Stähli, Olivier Muller, Marco Roffi, Lorenz Räber, Thomas F Lüscher
Background and Aims Dipeptidyl peptidase 3 (DPP3) is a protease involved in the degradation of angiotensin II which disturbs peripheral blood pressure regulation and compromises left ventricular function. This study examined the relationship of circulating DPP3 (cDPP3) with cardiogenic shock (CS) and mortality in patients presenting with acute coronary syndromes (ACS). Methods Plasma cDPP3 levels were
-
Heart Failure Medical Therapy Prior to Mitral Transcatheter Edge-to-Edge Repair: The STS/ACC Transcatheter Valve Therapy Registry Eur. Heart J. (IF 39.3) Pub Date : 2023-08-26 Anubodh S Varshney, Miloni Shah, Sreekanth Vemulapalli, Andrzej Kosinski, Ankeet S Bhatt, Alexander T Sandhu, Sameer Hirji, Ersilia M DeFilippis, Pinak B Shah, Mona Fiuzat, Patrick T O’Gara, Deepak L Bhatt, Tsuyoshi Kaneko, Michael M Givertz, Muthiah Vaduganathan
Background and Aims Guideline-directed medical therapy (GDMT) is recommended prior to mitral valve transcatheter edge-to-edge repair (MTEER) in patients with heart failure (HF) and severe functional mitral regurgitation (FMR). Whether MTEER is being performed on the background of optimal GDMT in clinical practice is unknown. Methods Patients with left ventricular ejection fraction (LVEF) < 50% who
-
Upgrade of right ventricular pacing to cardiac resynchronisation therapy in heart failure: a randomised trial Eur. Heart J. (IF 39.3) Pub Date : 2023-08-26 Béla Merkely, Robert Hatala, Jerzy K Wranicz, Gábor Duray, Csaba Földesi, Zoltán Som, Marianna Németh, Kinga Goscinska-Bis, László Gellér, Endre Zima, István Osztheimer, Levente Molnár, Júlia Karády, Gerhard Hindricks, Ilan Goldenberg, Helmut Klein, Mátyás Szigeti, Scott D Solomon, Valentina Kutyifa, Attila Kovács, Annamária Kosztin
Background and Aims De novo implanted cardiac resynchronisation therapy with defibrillator (CRT-D) reduces the risk of morbidity and mortality in patients with left bundle branch block, heart failure and reduced ejection fraction (HFrEF). However, among HFrEF patients with right ventricular pacing (RVP), the efficacy of CRT-D upgrade is uncertain. Methods In this multicentre, randomised, controlled
-
Efficacy of Ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis Eur. Heart J. (IF 39.3) Pub Date : 2023-08-25 Piotr Ponikowski, Robert J Mentz, Adrian F Hernandez, Javed Butler, Muhammad Shahzeb Khan, Dirk J van Veldhuisen, Bernard Roubert, Nicole Blackman, Tim Friede, Ewa A Jankowska, Stefan D Anker
Background and Aims Whereas a beneficial effect of intravenous ferric carboxymaltose (FCM) on symptoms and exercise capacity among patients with iron deficiency (ID) and heart failure (HF) has been consistently demonstrated, the effects of treatment on clinical events remain the subject of research. This meta-analysis aimed to characterize the effects of FCM therapy on hospitalizations and mortality
-
Competency-based cardiac imaging for patient-centred care. A statement of the European Society of Cardiology (ESC) Eur. Heart J. (IF 39.3) Pub Date : 2023-08-25 Mark Westwood, Ana G Almeida, Emanuele Barbato, Victoria Delgado, Santo Dellegrottaglie, Kevin F Fox, Luna Gargani, Kurt Huber, Pál Maurovich-Horvat, Jose L Merino, Richard Mindham, Denisa Muraru, Lis Neubeck, Robin Nijveldt, Michael Papadakis, Gianluca Pontone, Susanna Price, Giuseppe M C Rosano, Alexia Rossi, Leyla Elif Sade, Jeanette Schulz-Menger, Franz Weidinger, Stephan Achenbach, Steffen E Petersen
Imaging plays an integral role in all aspects of managing heart disease and cardiac imaging is a core competency of cardiologists. The adequate delivery of cardiac imaging services requires expertise in both imaging methodology – with specific adaptations to imaging of the heart – as well as intricate knowledge of heart disease. The European Society of Cardiology (ESC) and the European Association
-
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study Eur. Heart J. (IF 39.3) Pub Date : 2023-08-25 Nina Karia, Luke Howard, Martin Johnson, David G Kiely, James Lordan, Colm McCabe, Joanna Pepke-Zaba, Rose Ong, Michael Preiss, Daniel Knight, Vivek Muthurangu, J Gerry Coghlan
Background and Aims Interventional studies in pulmonary arterial hypertension completed to date have shown to be effective in symptomatic patients with significantly elevated mean pulmonary artery pressure (mPAP) (≥25 mmHg) and pulmonary vascular resistance (PVR) > 3 Wood Unit (WU). However, in health the mPAP does not exceed 20 mmHg and PVR is 2 WU or lower, at rest. The ESC/ERS guidelines have recently
-
Economic burden of cardiovascular diseases in the European Union: a population-based cost study Eur. Heart J. (IF 39.3) Pub Date : 2023-08-24 Ramon Luengo-Fernandez, Marjan Walli-Attaei, Alastair Gray, Aleksandra Torbica, Aldo P Maggioni, Radu Huculeci, Firoozeh Bairami, Victor Aboyans, Adam D Timmis, Panos Vardas, Jose Leal
Background and aims Cardiovascular disease (CVD) impacts significantly health and social care systems as well as society through premature mortality and disability, with patients requiring care from relatives. Previous pan- European estimates of the economic burden of CVD are now outdated. This study aims to provide novel, up-to-date evidence on the economic burden across the 27 European Union (EU)
-
Renal Function and Decongestion With Acetazolamide in Acute Decompensated Heart Failure: The ADVOR Trial Eur. Heart J. (IF 39.3) Pub Date : 2023-08-24 Evelyne Meekers, Jeroen Dauw, Pieter Martens, Sebastiaan Dhont, Frederik H Verbrugge, Petra Nijst, Jozine M ter Maaten, Kevin Damman, Alexandre Mebazaa, Gerasimos Filippatos, Frank Ruschitzka, W H Wilson Tang, Matthias Dupont, Wilfried Mullens
Background and aims In the ADVOR trial, acetazolamide improved decongestion in acute decompensated heart failure (ADHF). Whether the beneficial effects of acetazolamide are consistent across the entire range of renal function remains unclear. Methods This is a prespecified analysis of the ADVOR trial that randomized 519 patients with ADHF to intravenous acetazolamide or matching placebo on top of intravenous
-
Sodium-based paracetamol: impact on blood pressure, cardiovascular events, and all-cause mortality Eur. Heart J. (IF 39.3) Pub Date : 2023-08-23 Shishir Rao, Milad Nazarzadeh, Dexter Canoy, Yikuan Li, Jing Huang, Mohammad Mamouei, Gholamreza Salimi-Khorshidi, Aletta E Schutte, Bruce Neal, George Davey Smith, Kazem Rahimi
Background and Aims Effervescent formulations of paracetamol containing sodium bicarbonate have been reported to associate with increased blood pressure and a higher risk of cardiovascular diseases and all-cause mortality. Given the major implications of these findings, the reported associations were re-examined. Methods Using linked electronic health records data, a cohort of 475 442 UK individuals
-
Severe aortic stenosis detection by deep learning applied to echocardiography Eur. Heart J. (IF 39.3) Pub Date : 2023-08-23 Gregory Holste, Evangelos K Oikonomou, Bobak J Mortazavi, Andreas Coppi, Kamil F Faridi, Edward J Miller, John K Forrest, Robert L McNamara, Lucila Ohno-Machado, Neal Yuan, Aakriti Gupta, David Ouyang, Harlan M Krumholz, Zhangyang Wang, Rohan Khera
Background and Aims Early diagnosis of aortic stenosis (AS) is critical to prevent morbidity and mortality but requires skilled examination with Doppler imaging. This study reports the development and validation of a novel deep learning model that relies on two-dimensional (2D) parasternal long axis videos from transthoracic echocardiography without Doppler imaging to identify severe AS, suitable for
-
Women, lipids, and atherosclerotic cardiovascular disease: a call to action from the European Atherosclerosis Society Eur. Heart J. (IF 39.3) Pub Date : 2023-08-23 Jeanine E Roeters van Lennep, Lale S Tokgözoğlu, Lina Badimon, Sandra M Dumanski, Martha Gulati, Connie N Hess, Kirsten B Holven, Maryam Kavousi, Meral Kayıkçıoğlu, Esther Lutgens, Erin D Michos, Eva Prescott, Jane K Stock, Anne Tybjaerg-Hansen, Marieke J H Wermer, Marianne Benn
Cardiovascular disease is the leading cause of death in women and men globally, with most due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 years, ASCVD mortality is now increasing, with the fastest relative increase in middle-aged women. Missed or delayed diagnosis and undertreatment do not fully explain this burden of disease. Sex-specific factors, such as
-
Bicuspid aortic valve: long-term morbidity and mortality Eur. Heart J. (IF 39.3) Pub Date : 2023-08-23 Li-Tan Yang, Zi Ye, Muhammad Wajih Ullah, Joseph J Maleszewski, Christopher G Scott, Ratnasari Padang, Sorin V Pislaru, Vuyisile T Nkomo, Sunil V Mankad, Patricia A Pellikka, Jae K Oh, Veronique L Roger, Maurice Enriquez-Sarano, Hector I Michelena
Background and Aims Bicuspid aortic valve (BAV) is the most common congenital heart anomaly. Lifetime morbidity and whether long-term survival varies according to BAV patient-sub-groups are unknown. This study aimed to assess lifetime morbidity and long-term survival in BAV patients in the community. Methods The authors retrospectively identified all Olmsted County (Minnesota) residents with an echocardiographic
-
Temporal trends of cause-specific mortality after diagnosis of atrial fibrillation Eur. Heart J. (IF 39.3) Pub Date : 2023-08-22 Jianhua Wu, Ramesh Nadarajah, Yoko M Nakao, Kazuhiro Nakao, Chris Wilkinson, J Campbell Cowan, A John Camm, Chris P Gale
Background and Aims Reports of outcomes after atrial fibrillation (AF) diagnosis are conflicting. The aim of this study was to investigate mortality and hospitalisation rates following AF diagnosis over time, by cause, and by patient features. Methods Individuals aged ≥16 years with a first diagnosis of AF were identified from the UK Clinical Practice Research Datalink-GOLD dataset from Jan 1, 2001
-
Mineralocorticoid receptor antagonists with sodium–glucose co-transporter-2 inhibitors in heart failure: a meta-analysis Eur. Heart J. (IF 39.3) Pub Date : 2023-08-22 Mainak Banerjee, Indira Maisnam, Rimesh Pal, Satinath Mukhopadhyay
Background and Aims To investigate the cardiovascular effects of sodium–glucose co-transporter-2 inhibitors (SGLT2i) with concomitant mineralocorticoid receptor antagonist (MRA) use in heart failure (HF) regardless of ejection fraction (EF) and explore the risk of MRA-associated adverse events in individuals randomized to SGLT2i vs. placebo. Methods PubMed/MEDLINE, Web of Science, Embase, and clinical
-
Placing patient-reported outcomes at the centre of cardiovascular clinical practice: implications for quality of care and management Eur. Heart J. (IF 39.3) Pub Date : 2023-08-22 Philip Moons, Tone M Norekvål, Elena Arbelo, Britt Borregaard, Barbara Casadei, Bernard Cosyns, Martin R Cowie, Donna Fitzsimons, Alan G Fraser, Tiny Jaarsma, Paulus Kirchhof, Josepa Mauri, Richard Mindham, Julie Sanders, Francois Schiele, Aleksandra Torbica, Ann Dorthe Zwisler
Patient-reported outcomes (PROs) provide important insights into patients’ own perspectives about their health and medical condition, and there is evidence that their use can lead to improvements in the quality of care and to better-informed clinical decisions. Their application in cardiovascular populations has grown over the past decades. This statement describes what PROs are, and it provides an
-
Atlas of gut microbe-derived products from aromatic amino acids and risk of cardiovascular morbidity and mortality Eur. Heart J. (IF 39.3) Pub Date : 2023-08-22 Ina Nemet, Xinmin S Li, Arash Haghikia, Lin Li, Jennifer Wilcox, Kymberleigh A Romano, Jennifer A Buffa, Marco Witkowski, Ilja Demuth, Maximilian König, Elisabeth Steinhagen-Thiessen, Fredrik Bäckhed, Michael A Fischbach, W H Wilson Tang, Ulf Landmesser, Stanley L Hazen
Aims Precision microbiome modulation as a novel treatment strategy is a rapidly evolving and sought goal. The aim of this study is to determine relationships among systemic gut microbial metabolite levels and incident cardiovascular disease risks to identify gut microbial pathways as possible targets for personalized therapeutic interventions. Methods and results Stable isotope dilution mass spectrometry
-
Perivascular adipose tissue as a source of therapeutic targets and clinical biomarkers Eur. Heart J. (IF 39.3) Pub Date : 2023-08-21 Charalambos Antoniades, Dimitris Tousoulis, Marija Vavlukis, Ingrid Fleming, Dirk J Duncker, Etto Eringa, Olivia Manfrini, Alexios S Antonopoulos, Evangelos Oikonomou, Teresa Padró, Danijela Trifunovic-Zamaklar, Giuseppe De Luca, Tomasz Guzik, Edina Cenko, Ana Djordjevic-Dikic, Filippo Crea
Obesity is a modifiable cardiovascular risk factor, but adipose tissue (AT) depots in humans are anatomically, histologically, and functionally heterogeneous. For example, visceral AT is a pro-atherogenic secretory AT depot, while subcutaneous AT represents a more classical energy storage depot. Perivascular adipose tissue (PVAT) regulates vascular biology via paracrine cross-talk signals. In this
-
Epilepsy and long-term risk of arrhythmias Eur. Heart J. (IF 39.3) Pub Date : 2023-08-21 Jie Wang, Peiyuan Huang, Qingwei Yu, Jun Lu, Pinbo Liu, Yiping Yang, Zeying Feng, Jingjing Cai, Guoping Yang, Hong Yuan, Haibo Tang, Yao Lu
Background and Aims Previous evidence has mainly supported transient changes in cardiac function during interictal or peri-ictal phases in people with epilepsy, but the long-term risk of cardiac arrhythmias is poorly described. This study aimed to assess the long-term association of epilepsy with cardiac arrhythmias, considering the potential role of genetic predisposition and antiseizure medications
-
End-stage heart failure in congenitally corrected transposition of the great arteries: a multicentre study Eur. Heart J. (IF 39.3) Pub Date : 2023-08-18 Alexandra C van Dissel, Alexander R Opotowsky, Luke J Burchill, Jamil Aboulhosn, Jasmine Grewal, Adam M Lubert, Petra Antonova, Sangeeta Shah, Timothy Cotts, Anitha S John, William Aaron Kay, Christopher DeZorzi, Anthony Magalski, Frank Han, David Baker, Joseph Kay, Elizabeth Yeung, Isabelle Vonder Muhll, Stephen Pylypchuk, Marissa C Kuo, Jeremy Nicolarsen, Berardo Sarubbi, Flavia Fusco, Susan M Jameson
Background and Aims For patients with congenitally corrected transposition of the great arteries (ccTGA), factors associated with progression to end-stage congestive heart failure (CHF) remain largely unclear. Methods This multicentre, retrospective cohort study included adults with ccTGA seen at a congenital heart disease centre. Clinical data from initial and most recent visits were obtained. The
-
Inflammation in acute myocardial infarction: the good, the bad and the ugly Eur. Heart J. (IF 39.3) Pub Date : 2023-08-17 Michael A Matter, Francesco Paneni, Peter Libby, Stefan Frantz, Barbara E Stähli, Christian Templin, Alessandro Mengozzi, Yu-Jen Wang, Thomas M Kündig, Lorenz Räber, Frank Ruschitzka, Christian M Matter
Convergent experimental and clinical evidence have established the pathophysiological importance of pro-inflammatory pathways in coronary artery disease. Notably, the interest in treating inflammation in patients suffering acute myocardial infarction (AMI) is now expanding from its chronic aspects to the acute setting. Few large outcome trials have proven the benefits of anti-inflammatory therapies
-
Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy Eur. Heart J. (IF 39.3) Pub Date : 2023-08-16 Tzu-Yu Lai, Yu-Wen Hu, Ti-Hao Wang, Jui-Pin Chen, Cheng-Ying Shiau, Pin-I Huang, I Chun Lai, Ling-Ming Tseng, Nicole Huang, Chia-Jen Liu
Background and Aims Patients with left-sided breast cancer receive a higher mean heart dose (MHD) after radiotherapy, with subsequent risk of ischaemic heart disease. However, the optimum dosimetric predictor among cardiac substructures has not yet been determined. Methods and results This study retrospectively reviewed 2158 women with breast cancer receiving adjuvant radiotherapy. The primary endpoint
-
Arrhythmic mitral valve prolapse and mitral annular disjunction: pathophysiology, risk stratification, and management Eur. Heart J. (IF 39.3) Pub Date : 2023-08-10 Benjamin Essayagh, Avi Sabbag, Edward El-Am, João L Cavalcante, Hector I Michelena, Maurice Enriquez-Sarano
Mitral valve prolapse (MVP) is the most frequent valve condition but remains a conundrum in many aspects, particularly in regard to the existence and frequency of an arrhythmic form (AMVP) and its link to sudden cardiac death. Furthermore, the presence, frequency, and significance of the anatomic functional feature called mitral annular disjunction (MAD) have remained widely disputed. Recent case series
-
Clinical presentation of calmodulin mutations: the International Calmodulinopathy Registry Eur. Heart J. (IF 39.3) Pub Date : 2023-08-02 Lia Crotti, Carla Spazzolini, Mette Nyegaard, Michael T Overgaard, Maria-Christina Kotta, Federica Dagradi, Luca Sala, Takeshi Aiba, Mark D Ayers, Anwar Baban, Julien Barc, Cheyenne M Beach, Elijah R Behr, J Martijn Bos, Marina Cerrone, Peter Covi, Bettina Cuneo, Isabelle Denjoy, Birgit Donner, Adrienne Elbert, Håkan Eliasson, Susan P Etheridge, Megumi Fukuyama, Francesca Girolami, Robert Hamilton
Aims Calmodulinopathy due to mutations in any of the three CALM genes (CALM1–3) causes life-threatening arrhythmia syndromes, especially in young individuals. The International Calmodulinopathy Registry (ICalmR) aims to define and link the increasing complexity of the clinical presentation to the underlying molecular mechanisms. Methods and results The ICalmR is an international, collaborative, observational
-
Accelerated Rule-Out of acute Myocardial Infarction using prehospital copeptin and in-hospital troponin: The AROMI study Eur. Heart J. (IF 39.3) Pub Date : 2023-07-21 Claus Kjær Pedersen, Carsten Stengaard, Morten Thingemann Bøtker, Hanne Maare Søndergaard, Karen Kaae Dodt, Christian Juhl Terkelsen
Aims The present acute myocardial infarction (AMI) rule-out strategies are challenged by the late temporal release of cardiac troponin. Copeptin is a non-specific biomarker of endogenous stress and rises early in AMI, covering the early period where troponin is still normal. An accelerated dual-marker rule-out strategy combining prehospital copeptin and in-hospital high-sensitivity troponin T could
-
Global perspectives on heart disease rehabilitation and secondary prevention: a scientific statement from the Association of Cardiovascular Nursing and Allied Professions, European Association of Preventive Cardiology, and International Council of Cardiovascular Prevention and Rehabilitation Eur. Heart J. (IF 39.3) Pub Date : 2023-07-21 Rod S Taylor, Suzanne Fredericks, Ian Jones, Lis Neubeck, Julie Sanders, Noemi De Stoutz, David R Thompson, Deepti N Wadhwa, Sherry L Grace
Cardiovascular disease is a leading cause of death, morbidity, disability, and reduced health-related quality of life, as well as economic burden worldwide, with some 80% of disease burden occurring in the low- and middle-income country (LMIC) settings. With increasing numbers of people living longer with symptomatic disease, the effectiveness and accessibility of secondary preventative and rehabilitative
-
Balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension: a clinical consensus statement of the ESC working group on pulmonary circulation and right ventricular function Eur. Heart J. (IF 39.3) Pub Date : 2023-07-20 Irene M Lang, Arne K Andreassen, Asger Andersen, Helene Bouvaist, Gerry Coghlan, Pilar Escribano-Subias, Pavel Jansa, Grzegorz Kopec, Marcin Kurzyna, Hiromi Matsubara, Bernhard Christian Meyer, Massimiliano Palazzini, Marco C Post, Piotr Pruszczyk, Lorenz Räber, Marek Roik, Stephan Rosenkranz, Christoph B Wiedenroth, Carlo Redlin-Werle, Philippe Brenot
The current treatment algorithm for chronic thromboembolic pulmonary hypertension (CTEPH) as depicted in the 2022 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines on the diagnosis and treatment of pulmonary hypertension (PH) includes a multimodal approach of combinations of pulmonary endarterectomy (PEA), balloon pulmonary angioplasty (BPA) and medical therapies to
-
New recommendations of the International Committee of Medical Journal Editors: use of artificial intelligence. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-15 Fernando Alfonso,Filippo Crea
-
Artificial intelligence in detecting left atrial appendage thrombus by transthoracic echocardiography and clinical features: the Left Atrial Thrombus on Transoesophageal Echocardiography (LATTEE) registry. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-15 Konrad Pieszko,Jarosław Hiczkiewicz,Katarzyna Łojewska,Beata Uziębło-Życzkowska,Paweł Krzesiński,Monika Gawałko,Monika Budnik,Katarzyna Starzyk,Beata Wożakowska-Kapłon,Ludmiła Daniłowicz-Szymanowicz,Damian Kaufmann,Maciej Wójcik,Robert Błaszczyk,Katarzyna Mizia-Stec,Maciej Wybraniec,Katarzyna Kosmalska,Marcin Fijałkowski,Anna Szymańska,Mirosław Dłużniewski,Michał Kucio,Maciej Haberka,Karolina Kupczyńska
AIMS Transoesophageal echocardiography (TOE) is often performed before catheter ablation or cardioversion to rule out the presence of left atrial appendage thrombus (LAT) in patients on chronic oral anticoagulation (OAC), despite associated discomfort. A machine learning model [LAT-artificial intelligence (AI)] was developed to predict the presence of LAT based on clinical and transthoracic echocardiography
-
Heart failure and socioeconomic status: global differences and inequalities. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-15 Rocco Vergallo,Carlo Patrono
-
Diagnostic management of acute pulmonary embolism: a prediction model based on a patient data meta-analysis. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-15 Nick van Es,Toshihiko Takada,Noémie Kraaijpoel,Frederikus A Klok,Milou A M Stals,Harry R Büller,D Mark Courtney,Yonathan Freund,Javier Galipienzo,Grégoire Le Gal,Waleed Ghanima,Menno V Huisman,Jeffrey A Kline,Karel G M Moons,Sameer Parpia,Arnaud Perrier,Marc Righini,Helia Robert-Ebadi,Pierre-Marie Roy,Phil S Wells,Kerstin de Wit,Maarten van Smeden,Geert-Jan Geersing
AIMS Risk stratification is used for decisions regarding need for imaging in patients with clinically suspected acute pulmonary embolism (PE). The aim was to develop a clinical prediction model that provides an individualized, accurate probability estimate for the presence of acute PE in patients with suspected disease based on readily available clinical items and D-dimer concentrations. METHODS AND
-
The European Heart Journal's top contributing institutions: the Royal Brompton and Harefield hospitals, UK. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-14
-
Vegetarian and vegan diets: benefits and drawbacks Eur. Heart J. (IF 39.3) Pub Date : 2023-07-14 Tian Wang, Andrius Masedunskas, Walter C Willett, Luigi Fontana
Plant-based diets have become increasingly popular thanks to their purported health benefits and more recently for their positive environmental impact. Prospective studies suggest that consuming vegetarian diets is associated with a reduced risk of developing cardiovascular disease (CVD), diabetes, hypertension, dementia, and cancer. Data from randomized clinical trials have confirmed a protective
-
Eliminating atherosclerotic cardiovascular disease residual risk. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-14 Michael E Makover,Stanislaw Surma,Maciej Banach,Peter P Toth
-
Cardiometabolic risk management: insights from a European Society of Cardiology Cardiovascular Round Table. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-14 Francesco Cosentino,Subodh Verma,Philip Ambery,Marianne Bach Treppendahl,Martin van Eickels,Stefan D Anker,Michele Cecchini,Paola Fioretto,Per-Henrik Groop,David Hess,Kamlesh Khunti,Carolyn S P Lam,Isabelle Richard-Lordereau,Lars H Lund,Paul McGreavy,Philip N Newsome,Naveed Sattar,Scott Solomon,Franz Weidinger,Faiez Zannad,Andreas Zeiher
Metabolic comorbidities are common in patients with cardiorenal disease; they can cause atherosclerotic cardiovascular disease (ASCVD), speed progression, and adversely affect prognosis. Common comorbidities are Type 2 diabetes mellitus (T2DM), obesity/overweight, chronic kidney disease (CKD), and chronic liver disease. The cardiovascular system, kidneys, and liver are linked to many of the same risk
-
Addressing the pandemic of atrial fibrillation: optimization of catheter ablation and new therapeutic targets. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-14 Filippo Crea
-
Should I stent or should I go? Eur. Heart J. (IF 39.3) Pub Date : 2023-07-14 Daniela Pedicino,Giovanna Liuzzo
-
Management of patients on antithrombotic therapy with severe infections: a joint clinical consensus statement of the ESC Working Group on Thrombosis, the ESC Working Group on Atherosclerosis and Vascular Biology, and the International Society on Thrombosis and Haemostasis. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-13 Bruna Gigante,Jerrold H Levy,Eric van Gorp,Alessandro Bartoloni,Marie-Luce Bochaton-Piallat,Magnus Bäck,Hugo Ten Cate,Christina Christersson,José Luis Ferreiro,Tobias Geisler,Esther Lutgens,Sam Schulman,Robert F Storey,Jecko Thachil,Gemma Vilahur,Patricia C Liaw,Bianca Rocca
Patients with severe infections and a pre-existing indication for antithrombotic therapy, i.e. antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical counselling among coagulation, infectious disease, and cardiology specialists, due to sepsis-induced coagulopathy that frequently occurs. Bacterial and viral pathogens constitute an increasing threat to global public
-
Residual environmental risk in patients with cardiovascular disease: an overlooked paradigm. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-11 Sadeer Al-Kindi,Francesco Paneni,Robert D Brook,Sanjay Rajagopalan
-
Erratum to: Smoking habit change after cancer diagnosis: effect on cardiovascular risk. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-11
-
Ethnicity, consanguinity, and genetic architecture of hypertrophic cardiomyopathy Eur. Heart J. (IF 39.3) Pub Date : 2023-07-11 Mona Allouba, Roddy Walsh, Alaa Afify, Mohammed Hosny, Sarah Halawa, Aya Galal, Mariam Fathy, Pantazis I Theotokis, Ahmed Boraey, Amany Ellithy, Rachel Buchan, Risha Govind, Nicola Whiffin, Shehab Anwer, Ahmed ElGuindy, James S Ware, Paul J R Barton, Magdi Yacoub, Yasmine Aguib
Aims Hypertrophic cardiomyopathy (HCM) is characterized by phenotypic heterogeneity that is partly explained by the diversity of genetic variants contributing to disease. Accurate interpretation of these variants constitutes a major challenge for diagnosis and implementing precision medicine, especially in understudied populations. The aim is to define the genetic architecture of HCM in North African
-
Focus on ischaemic heart disease: from mechanisms to prevention and treatment. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-07 Filippo Crea
-
Histiocytes set on the heart: cardiac complications of Erdheim-Chester disease. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-07 Matthew Collin
-
Diet, cardiovascular disease, and mortality in 80 countries Eur. Heart J. (IF 39.3) Pub Date : 2023-07-07 Andrew Mente, Mahshid Dehghan, Sumathy Rangarajan, Martin O’Donnell, Weihong Hu, Gilles Dagenais, Andreas Wielgosz, Scott A Lear, Li Wei, Rafael Diaz, Alvaro Avezum, Patricio Lopez-Jaramillo, Fernando Lanas, Sumathi Swaminathan, Manmeet Kaur, K Vijayakumar, Viswanathan Mohan, Rajeev Gupta, Andrzej Szuba, Romaina Iqbal, Rita Yusuf, Noushin Mohammadifard, Rasha Khatib, Nafiza Mat Nasir, Kubilay Karsidag
Aims To develop a healthy diet score that is associated with health outcomes and is globally applicable using data from the Prospective Urban Rural Epidemiology (PURE) study and replicate it in five independent studies on a total of 245 000 people from 80 countries. Methods and results A healthy diet score was developed in 147 642 people from the general population, from 21 countries in the PURE study
-
Identifying nutritional priorities for global health: time for a more PURE focus on protective foods. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-06 Dariush Mozaffarian
-
Sudden cardiac arrest in adult congenital heart disease: a challenge to be tackled. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-06 Victor Waldmann,Kumar Narayanan,Eloi Marijon
-
Outcomes of out-of-hospital cardiac arrest in adult congenital heart disease: a Danish nationwide study Eur. Heart J. (IF 39.3) Pub Date : 2023-07-06 Carlo Alberto Barcella, Daniel Mølager Christensen, Lars Idorn, Nishan Mudalige, Morten Malmborg, Frederik Folke, Christian Torp-Pedersen, Gunnar Gislason, Mohamad El-Chouli
Aims The risk, characteristics, and outcome of out-of-hospital cardiac arrest (OHCA) in patients with congenital heart disease (CHD) remain scarcely investigated. Methods and results An epidemiological registry-based study was conducted. Using time-dependent Cox regression models fitted with a nested case–control design, hazard ratios (HRs) with 95% confidence intervals of OHCA of presumed cardiac
-
The CODE-EHR global framework: lifting the veil on health record data. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-06 Folkert W Asselbergs,Dipak Kotecha
-
Targeting sacubitril/valsartan for heart failure with mildly reduced or preserved ejection fraction. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-05 Stephen J Greene,Gregg C Fonarow
-
Translating HARMS2-AF into benefits for our atrial fibrillation patients and the general public: challenges and opportunities. Eur. Heart J. (IF 39.3) Pub Date : 2023-07-05 Gregory M Marcus
-
Triglyceride-rich remnant lipoproteins are more atherogenic than LDL per particle: is this important? Eur. Heart J. (IF 39.3) Pub Date : 2023-07-05 Anne Tybjærg-Hansen,Børge G Nordestgaard,Mette Christoffersen
-
Heyde syndrome: treat aortic valve disease to stop gastrointestinal bleeding? Eur. Heart J. (IF 39.3) Pub Date : 2023-07-05 Lara Waldschmidt,Moritz Seiffert